A case of fatal hyperammonaemic encephalopathy in a patient with end-stage Multiple Myeloma treated with daratumumab

Passucci, Mauro; Fazio, Francesca; Petrucci, Maria Teresa

doi:10.4084/mjhid.2023.012

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion2

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, due to the use of HDT with ASCT, it is possible to increase the number of "very long responders" i.e. FL patients with PFS longer than 10 years after the end of therapy [8].…”

Section: Discussionmentioning

confidence: 99%

Fifteen-year remission in a patient with follicular lymphoma after high-dose chemotherapy with autologous stem cell transplantation as a first-line treatment

Smolyaninova

2023

Open J Clin Med Case Rep

View full text Add to dashboard Cite

show abstract

“…Therefore, due to the use of HDT with ASCT, it is possible to increase the number of "very long responders" i.e. FL patients with PFS longer than 10 years after the end of therapy [8].…”

Section: Discussionmentioning

confidence: 99%

Fifteen-year remission in a patient with follicular lymphoma after high-dose chemotherapy with autologous stem cell transplantation as a first-line treatment

Smolyaninova

2023

Open J Clin Med Case Rep

View full text Add to dashboard Cite

show abstract

“…In most cases, neurological manifestations of MM are due to hypercalcemia, hyperviscosity, infection, or medication side effects. Hyperammonemia due to MM is often associated with advanced stages of disease (International Staging System (ISS)-3), plasma cells in the peripheral circulation, cytological abnormalities, and extramedullary locations [ 11 , 12 ]. Patients with an advanced stage of the disease and poor prognostic factors such as 1q gain are more susceptible to the development of hyperammonemia.…”

Section: Discussionmentioning

confidence: 99%

Hyperammonemic Encephalopathy: A Rare Presentation of Relapsed Multiple Myeloma

Menakuru¹,

Atta²,

Ammannagari³

et al. 2023

J Hematol

View full text Add to dashboard Cite

Hyperammonemia is a rare cause of encephalopathy in multiple myeloma in the absence of hepatic involvement. This is the only reported case of a 74-year-old man who presented with multiple myeloma and achieved complete remission but developed hyperammonemia afterward. He was aggressively treated with a combination of chemotherapy and immunotherapy, with a resolution of his encephalopathy; however, within one month, he relapsed with encephalopathy. He ultimately decided to pursue comfort-care measures. The authors conclude that hyperammonemia in multiple myeloma is a rare but important differential in patients with encephalopathy of unknown causes. Aggressive treatment is of the utmost importance due to the high mortality associated with the condition.

show abstract

A case of fatal hyperammonaemic encephalopathy in a patient with end-stage Multiple Myeloma treated with daratumumab

Abstract: n.

Cited by 2 publications

References 9 publications

Fifteen-year remission in a patient with follicular lymphoma after high-dose chemotherapy with autologous stem cell transplantation as a first-line treatment

Fifteen-year remission in a patient with follicular lymphoma after high-dose chemotherapy with autologous stem cell transplantation as a first-line treatment

Hyperammonemic Encephalopathy: A Rare Presentation of Relapsed Multiple Myeloma

Contact Info

Product

Resources

About